American Heart Journal
Volume 155, Issue 2 , Pages 388-394 , February 2008

Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)–3 trial

  • Giovanni Pedrazzini, MD

      Affiliations

    • Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland
    • ,
  • Eugenio Santoro, MS

      Affiliations

    • Department of Epidemiology, Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy
    • ,
  • Roberto Latini, MD

      Affiliations

    • Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy
    • Department of Medicine, New York Medical College, Valhalla, NY
    • ,
  • Laurie Fromm, PharmD

      Affiliations

    • Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy
    • ,
  • Maria Grazia Franzosi, BiolScD

      Affiliations

    • Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy
    • ,
  • Tiziano Mocetti, MD

      Affiliations

    • Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland
    • ,
  • Lidia Staszewsky, MD

      Affiliations

    • Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy
    • ,
  • Simona Barlera, MS

      Affiliations

    • Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy
    • ,
  • Gianni Tognoni, MD

      Affiliations

    • Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy
    • ,
  • Aldo P. Maggioni, MD

      Affiliations

    • ANMCO Research Center, Florence, Italy
    • Corresponding Author InformationReprint requests: Aldo P. Maggioni, MD, ANMCO Research Center, Via La Marmora, 34-50121 Florence, Italy.
    • ,
  • for the GISSI-3 Investigators

      Affiliations

    • A complete list of GISSI-3 collaborators was published in The Lancet (1994;343:1115-22). The GISSI is endorsed by the Associazione Nazionale Medici Cardiologi Ospedalieri and by the “Mario Negri” Institute for Pharmacological Research.

Received 6 July 2007 ,Accepted 12 October 2007.

References 

  1. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985;6:199–226
  2. ISIS-1 (First International Study of Infarct Survival) Collaborative Group.. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66
  3. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.. Lancet. 1986;1:397–402
  4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.. Lancet. 1988;2:349–360
  5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311–322
  6. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65–67
  7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction.. Lancet. 1992;339:753–770
  8. Kleiman NS, White HD, Ohman EM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation. 1994;90:2568–2665
  9. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115–1122
  10. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678–684
  11. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.. Lancet. 1995;345:669–685
  12. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100000 patients in randomized trials. Circulation. 1998;97:2202–2212
  13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn 6 weeks after acute myocardial infarction. The GISSI-3 trial. J Am Coll Cardiol. 1996;27:337–344
  14. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Am Coll Cardiol. 1999;33:598–604
  15. Leri A, Claudio PP, Li Q, et al. Stretch mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest. 1998;101:1326–1342
  16. Pfeffer MA, Hennekens CH. When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol. 1995;75:1173–1175
  17. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995;92:3132–3137
  18. Kleiman NS, Terrin M, Mueller H, et al. Mechanisms of early death despite thrombolytic therapy: experience from the thrombolysis in myocardial infarction phase II (TIMI II) study. J Am Coll Cardiol. 1992;19:1129–1135
  19. Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) Study. J Am Coll Cardiol. 1995;25:1963–1968
  20. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States national registry of myocardial infarction. J Am Coll Cardiol. 1996;27:1321–1326
  21. Zahger D, Milgalter E. Clinical problem-solving. A broken heart. N Engl J Med. 1996;334:319–321
  22. Stevenson WG, Linssen GC, Havenith MG, et al. The spectrum of death after myocardial infarction: a necropsy study. Am Heart J. 1989;118:1182–1188
  23. Coats AJ, Adamopoulos S. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure. Cardiovasc Drugs Ther. 1994;8:685–692
  24. St John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96:3294–3299
  25. Cody RJ, Covita A, Schaer G, et al. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. Am Heart J. 1982;104:1180–1183
  26. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–2582
  27. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618–2626
  28. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717
  29. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  30. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med. 1993;329:1442–1448
  31. Malacrida R, Genoni M, Maggioni AP, et al. A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med. 1998;338:8–14
  32. Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)–2 Data Base. Circulation. 1993;88:416–429
  33. Weaver WD, White HD, Wilcox RG, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA. 1996;275:777–782
  34. Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993;22:1788–1794

PII: S0002-8703(07)00828-9

doi: 10.1016/j.ahj.2007.10.015

American Heart Journal
Volume 155, Issue 2 , Pages 388-394 , February 2008

Article Tools

* Image Usage & Resolution